Omnio AB

Omnio AB is a biopharmaceutical company specializing in the development of new drug products based on the pro-inflammatory and immunoregulatory effects of the protein plasminogen. Omnio focuses on developing recombinant plasminogen for chronic wound healing, where initial physician-led studies of patients with chronic wounds have shown great potential. We develop disruptive treatments that improve lives while lowering the overall cost of health care with plasminogen-based therapeutics. Omnio is led by a team of life science entrepreneurs with extensive experience in immunology, partnerships and drug discovery collaborations. Omnio is developing recombinant plasminogen for treatment of chronic wounds. Our ambition is to change today's wound healing treatment and provide an effective alternative to patients where effective bioactive treatment is lacking. Unlike other products available on the market, plasminogen has been shown to be a key regulatory molecule that activates all stages of the wound healing process. We focus on delivering transformative treatment for chronic wounds and where there is little to no pharmacologically active treatment available today.